Literature DB >> 16598768

CK2 signaling in androgen-dependent and -independent prostate cancer.

Guixia Wang1, Kashif A Ahmad, Gretchen Unger, Joel W Slaton, Khalil Ahmed.   

Abstract

Protein serine/threonine kinase casein kinase 2 (CK2) is a key player in cell growth and proliferation but is also a potent suppressor of apoptosis. CK2 has been found to be dysregulated in all the cancers that have been examined, including prostate cancer. Investigations of CK2 signaling in the prostate were originally initiated in this laboratory, and these studies have identified significant functional activities of CK2 in relation to normal prostate growth and to the pathobiology of androgen-dependent and -independent prostate cancer. We present a brief overview of these developments in the context of prostate biology. An important outcome of these studies is the emerging concept that CK2 can be effectively targeted for cancer therapy. Copyright 2006 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16598768     DOI: 10.1002/jcb.20847

Source DB:  PubMed          Journal:  J Cell Biochem        ISSN: 0730-2312            Impact factor:   4.429


  16 in total

Review 1.  Emergence of protein kinase CK2 as a key target in cancer therapy.

Authors:  Janeen H Trembley; Zhong Chen; Gretchen Unger; Joel Slaton; Betsy T Kren; Carter Van Waes; Khalil Ahmed
Journal:  Biofactors       Date:  2010 May-Jun       Impact factor: 6.113

Review 2.  Protein kinase CK2--a key suppressor of apoptosis.

Authors:  Kashif A Ahmad; Guixia Wang; Gretchen Unger; Joel Slaton; Khalil Ahmed
Journal:  Adv Enzyme Regul       Date:  2008-04-30

3.  Impact of protein kinase CK2 on inhibitor of apoptosis proteins in prostate cancer cells.

Authors:  Guixia Wang; Kashif A Ahmad; Nathan H Harris; Khalil Ahmed
Journal:  Mol Cell Biochem       Date:  2008-06-24       Impact factor: 3.396

4.  Phosphoproteome Integration Reveals Patient-Specific Networks in Prostate Cancer.

Authors:  Justin M Drake; Evan O Paull; Nicholas A Graham; John K Lee; Bryan A Smith; Bjoern Titz; Tanya Stoyanova; Claire M Faltermeier; Vladislav Uzunangelov; Daniel E Carlin; Daniel Teo Fleming; Christopher K Wong; Yulia Newton; Sud Sudha; Ajay A Vashisht; Jiaoti Huang; James A Wohlschlegel; Thomas G Graeber; Owen N Witte; Joshua M Stuart
Journal:  Cell       Date:  2016-08-04       Impact factor: 41.582

5.  Protein B23/nucleophosmin/numatrin nuclear dynamics in relation to protein kinase CK2 and apoptotic activity in prostate cells.

Authors:  Guixia Wang; Yunqian Pan; Kashif A Ahmad; Khalil Ahmed
Journal:  Biochemistry       Date:  2010-05-11       Impact factor: 3.162

6.  Protein kinase CK2 in development and differentiation.

Authors:  Claudia Götz; Mathias Montenarh
Journal:  Biomed Rep       Date:  2016-12-19

Review 7.  Regulation of cellular proliferation in acute lymphoblastic leukemia by Casein Kinase II (CK2) and Ikaros.

Authors:  Chandrika Gowda; Chunhua Song; Malika Kapadia; Jonathon L Payne; Tommy Hu; Yali Ding; Sinisa Dovat
Journal:  Adv Biol Regul       Date:  2016-09-18

Review 8.  Protein kinase CK2 in health and disease: CK2: a key player in cancer biology.

Authors:  J H Trembley; G Wang; G Unger; J Slaton; K Ahmed
Journal:  Cell Mol Life Sci       Date:  2009-06       Impact factor: 9.261

9.  Nanocapsule-delivered Sleeping Beauty mediates therapeutic Factor VIII expression in liver sinusoidal endothelial cells of hemophilia A mice.

Authors:  Betsy T Kren; Gretchen M Unger; Lucas Sjeklocha; Alycia A Trossen; Vicci Korman; Brenda M Diethelm-Okita; Mark T Reding; Clifford J Steer
Journal:  J Clin Invest       Date:  2009-06-08       Impact factor: 14.808

Review 10.  Poly(malic acid) nanoconjugates containing various antibodies and oligonucleotides for multitargeting drug delivery.

Authors:  Julia Y Ljubimova; Manabu Fujita; Alexander V Ljubimov; Vladimir P Torchilin; Keith L Black; Eggehard Holler
Journal:  Nanomedicine (Lond)       Date:  2008-04       Impact factor: 5.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.